{
    "doi": "https://doi.org/10.1182/blood.V106.11.1106.1106",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=537",
    "start_url_page_num": 537,
    "is_scraped": "1",
    "article_title": "Emerging Marrow Fibrosis Is an Early Indicator of Imatinib Failure and Shortened Survival Time in CML Independent of Hematologic, Cytogenetic and Molecular Response. ",
    "article_date": "November 16, 2005",
    "session_type": "Poster Sessions",
    "topics": [
        "cytogenetics",
        "fibrosis",
        "imatinib mesylate",
        "interferon-alpha",
        "cytarabine",
        "hydroxyurea",
        "bcr-abl tyrosine kinase",
        "bone marrow biopsy",
        "busulfan",
        "disease remission"
    ],
    "author_names": [
        "Guntram Buesche",
        "Ruediger Hehlmann",
        "Arnold Ganser",
        "Hartmut Hecker",
        "Mathias Freund",
        "Hermann Heimpel",
        "Barbara Heinze",
        "Dorothea Gadzicki",
        "Brigitte Schlegelberger",
        "Christa Fonatsch",
        "Bernd Frye",
        "Andreas Tobler",
        "Axel Georgii",
        "Hans H. Kreipe"
    ],
    "author_affiliations": [
        [
            "Institut fuer Pathologie, Medizinische Hochschule Hannover, Hannover, Germany"
        ],
        [
            "III. Medizinische Klinik, Fakultaet fuer Klinische Medizin Mannheim, Universita\u0308t Heidelberg, Mannheim, Germany"
        ],
        [
            "Klinik fuer Haematologie, Haemostaseologie und Onkologie, Medizinische Hochschule Hannover, Hannover, Germany"
        ],
        [
            "Institut fuer Biometrie, Medizinische Hochschule Hannover, Hannover, Germany"
        ],
        [
            "Abteilung fuer Haematologie und Onkologie, Klinik fuer Innere Medizin, Universitaet Rostock, Rostock, Germany"
        ],
        [
            "Abteilung fuer Innere Medizin III, Klinikum der Universitaet Ulm, Ulm, Germany"
        ],
        [
            "Tumorzytogenetiklabor, Abteilung fuer Innere Medizin III, Universitaet Ulm, Ulm, Germany"
        ],
        [
            "Institut fuer Zell- und Molekularpathologie, Medizinische Hochschule Hannover, Hannover, Germany"
        ],
        [
            "Institut fuer Zell- und Molekularpathologie, Medizinische Hochschule Hannover, Hannover, Germany"
        ],
        [
            "Institut fuer Medizinische Biologie, Medizinische Universitaet Wien, Wien, Austria"
        ],
        [
            "Institut fuer Pathologie, Medizinische Hochschule Hannover, Hannover, Germany"
        ],
        [
            "Haematologisches Zentrallabor, Inselspital, Universitaet Bern, Bern, Switzerland"
        ],
        [
            "Institut fuer Pathologie, Medizinische Hochschule Hannover, Hannover, Germany"
        ],
        [
            "Institut fuer Pathologie, Medizinische Hochschule Hannover, Hannover, Germany"
        ]
    ],
    "first_author_latitude": "52.3722628",
    "first_author_longitude": "9.7625301",
    "abstract_text": "In chronic myeloid leukemia (CML), imatinib may reverse bone marrow fibrosis (MF) that has occurred before start of therapy. The risk and prognostic relevance of MF evolving during imatinib treatment are unclear as yet. Bone marrow biopsies (n = 1509) taken prospectively from Ph+ CML patients (n = 605) were examined for MF before and during therapy. 107 patients were treated with 400 mg imatinib / day, 208 with interferon-alpha +/\u2212 cytosine arabinoside, 154 with hydroxyurea and 136 with busulfan. Imatinib and interferon-alpha +/\u2212 cytosine arabinoside were significantly more effective than the other types of therapy regarding reversal of initial MF (P < 0.000005). During the follow-up period of 3 years, imatinib monotherapy was not superior to interferon-alpha or hydroxyurea in preventing evolution of MF: MF affected more than 20 % of patients and developed from small foci with increased fiber deposition to full-stage fibrosis within 1 \u2013 2 years. Hematologic, cytogenetic and molecular response did not protect against evolution of MF as long as a complete molecular remission (i.e. bcr/abl negativity) was not achieved. Evolving MF was an independent significant predictor of therapy resistance and shortened survival time of patients irrespective of the type of treatment (P < 0.00005). Conclusion: Although imatinib reverses initial MF in CML, MF may evolve during imatinib monotherapy indicating an unfavorable course of disease independent of hematologic, cytogenetic and molecular response."
}